Sangamo Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
29/10/2024 03:08
* Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected
to show
a rise in quarterly revenue when it reports results on October
30 (estimated) for the period ending September 30 2024
* The Richmond California California-based company is
expected to
report a 90.9% increase in revenue to $17.943 million from $9.4
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sangamo Therapeutics Inc
is
for a loss of 3 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $3.00, above its last closing price
of $2.04.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.15 -0.15 -0.18 Missed -23.5
Mar. 31 2024 -0.22 -0.21 -0.27 Missed -26.3
Jan. 1 0001 -0.26 -0.34 Missed -32.7
Sep. 30 2023 -0.31 -0.32 -0.59 Missed -84.4
Jun. -0.35 -0.34 -0.66 Missed -92.7
30 2023
Mar. 31 2023 -0.32 -0.33 0.12 Beat 136.6
Dec. 31 2022 -0.35 -0.36 -0.32 Beat 11.1
Sep. 30 2022 -0.34 -0.36 -0.34 Beat 4.3
This summary was machine generated October 29 at 03:08 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)